Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (8): 107-116.doi: 10.6040/j.issn.1671-7554.0.2024.0576

Previous Articles    

Gastric mucinous adenocarcinoma of lung has unique clinical and pathological characteristics

HAO Xiaomeng1, YU Zeyuan2, ZHANG Xiaofang1,2   

  1. 1. Department of Pathology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    2. Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan 250012, Shandong, China
  • Published:2024-09-20

PDF (PC)

430

Abstract: Objective To investigate the morphological characteristics, clinicopathological features, genetic alterations, and clinical outcomes of gastric mucinous adenocarcinoma(GMA), so as to supply personalized treatment for lung mucinous adenocarcinoma. Methods A total of 48 cases of invasive non-mucinous lung adenocarcinoma(INMA)and 40 cases of invasive mucinous adenocarcinoma(IMA)were retrospectively analyzed. The IMA cases included 30 cases of simple invasive mucinous adenocarcinoma(SIMA)and 10 cases of mucinous and non-mucinous mixed adenocarcinoma(MNMA). SIMA was further categorized into GMA, columnar cell mucinous adenocarcinoma(CMA), and mixed simple invasive mucinous adenocarcinoma(MSIMA). The clinicopathological data from the patients were collected. Immunohistochemical analysis was performed on all paraffin-embedded samples to detect the expressions of mucin 5ac(MUC5ac), mucin 6(MUC6), thyroid transcription factor-1(TTF-1), cytokeratin 7(CK7), and cytokeratin 5/6(CK5/6). Additionally, polymerase chain reaction(PCR)or next-generation sequencing(NGS)was conducted to detect lung cancer-related genes. Results Compared with CMA,MSIMA,MNMA and INMA, the mean diameter of GMA was significantly smaller and the age of onset was slightly higher. Most of GMA occured in the lower lobes of the lungs. The positive rate of MUC6 in GMA was 92.93%, which was significantly higher than those in CMA(8.33%), MNMA(20.00%), and INMA(0%), with a statistically significant difference(P<0.001). The expression rates of TTF-1 and CK7 in GMA were significantly lower than those in MNMA and INMA(P<0.001). KRAS gene mutation rate in GMA was higher than that in CMA, MNMA, and INMA. Additionally, MUC6 expression was positively correlated with KRAS gene mutations(Pearson correlation coefficient= 0.590). Conclusion GMA is characterized by small tumor size, high occurrence rate in the lower lobe of the lung, high MUC6 expression, and high KRAS gene mutation rate. These unique pathological, clinical, and molecular features suggest that GMA should be considered a distinct subtype.

Key words: Lung, Invasive mucinous adenocarcinoma, Human mucin 6, Thyroid transcription factor-1, KRAS gene

CLC Number: 

  • R365
[1] 孟健丽, 王庆港. 生物信息学方法探讨VPS72在肺腺/鳞癌中的表达及潜在作用机制[J]. 山东大学学报(医学版), 2023, 61(8): 40-49. MENG Jianli, WANG Qinggang. Expression and potential mechanism of VPS72 in lung adenocarcinoma/squamous cell carcinoma by integrated bioinformatics analysis[J]. Journal of Shandong University(Health Sciences), 2023, 61(8): 40-49.
[2] WHO Classifications of Tumours Editorial Board. Thoracic tumours[M]. Lyon: International Agency for Research on Cancer, 2021.
[3] Chang WC, Zhang YZ, Nicholson AG. Pulmonary invasive mucinous adenocarcinoma[J]. Histopathology, 2024, 84(1): 18-31.
[4] Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases[J]. Mod Pathol, 2011, 24(5): 653-664.
[5] Chang JC, Offin M, Falcon C, et al. Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes[J]. Clin Cancer Res, 2021, 27(14): 4066-4076.
[6] Watanabe H, Saito H, Yokose T, et al. Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma[J]. Ann Thorac Surg, 2015, 99(3): 975-981.
[7] Kishikawa S, Hayashi T, Saito T, et al. Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma[J]. Mod Pathol, 2021, 34(4): 786-797.
[8] Gow CH, Hsieh MS, Liu YN, et al. Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma[J]. Cancers, 2021, 13(16): 4103. doi:10.3390/cancers13164103.
[9] Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases[J]. Mod Pathol, 2011, 24(5): 653-664.
[10] Lee HY, Cha MJ, Lee KS, et al. Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas[J]. J Thorac Oncol, 2016, 11(7): 1064-1073.
[11] Matsui T, Sakakura N, Koyama S, et al. Comparison of surgical outcomes between invasive mucinous and non-mucinous lung adenocarcinoma[J]. Ann Thorac Surg, 2021, 112(4): 1118-1126.
[12] Kuruma A, Kodama M, Hori Y, et al. Gastric-type adenocarcinoma of the uterine cervix associated with poor response to definitive radiotherapy[J]. Cancers, 2022, 15(1): 170. doi:10.3390/cancers15010170.
[13] Ehmann S, Sassine D, Straubhar AM, et al. Gastric-type adenocarcinoma of the cervix: clinical outcomes and genomic drivers[J]. Gynecol Oncol, 2022, 167(3): 458-466.
[14] Goto E, Takamochi K, Kishikawa S, et al. Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics[J]. Lung Cancer, 2023, 184: 107348. doi:10.1016/j.lungcan.2023.107348.
[15] Boland JM, Maleszewski JJ, Wampfler JA, et al. Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis[J]. Hum Pathol, 2018, 71: 8-19. doi:10.1016/j.humpath.2017.08.002.
[16] Buettner R. Invasive mucinous adenocarcinoma: genetic insights into a lung cancer entity with distinct clinical behavior and genomic features[J]. Mod Pathol, 2022, 35(2): 138-139.
[17] Kim M, Hwang J, Kim KA, et al. Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement[J]. Mod Pathol, 2022, 35(2): 202-209.
[18] Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification[J]. J Thorac Oncol, 2011, 6(9): 1496-1504.
[19] Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases[J]. Mod Pathol, 2011, 24(5): 653-664.
[20] Battista S, Ambrosio MR, Limarzi F, et al. Molecular alterations in gastric preneoplastic lesions and early gastric cancer[J]. Int J Mol Sci, 2021, 22(13): 6652. doi:10.3390/ijms22136652.
[21] Wang S, Zhou X, Niu S, et al. Assessment of HER2 in gastric-type endocervical adenocarcinoma and its prognostic significance[J]. Mod Pathol, 2023, 36(6): 100148. doi:10.1016/j.modpat.2023.100148.
[22] Buyuk M, Ozluk Y, Bakkaloglu DV, et al. Evaluation of MUC1, MUC2, MUC5AC, and MUC6 expression differences in lung adenocarcinoma subtypes by using a final immunoreactivity score(FIRS)[J]. Turk Patoloji Derg, 2023, 39(1): 64-74.
[23] Kim YK, Shin DH, Kim KB, et al. MUC5AC and MUC5B enhance the characterization of mucinous adenocarcinomas of the lung and predict poor prognosis[J]. Histopathology, 2015, 67(4): 520-528.
[24] Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350(21): 2129-2139.
[25] Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.
[26] Chalela R, Curull V, Enríquez C, et al. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy[J]. J Thorac Dis, 2017, 9(7): 2142-2158.
[27] Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches[J]. Ann Oncol, 2021, 32(9): 1101-1110.
[28] Dias Carvalho P, Machado AL, Martins F, et al. Targeting the tumor microenvironment: an unexplored strategy for mutant KRAS tumors[J]. Cancers, 2019, 11(12): 2010. doi:10.3390/cancers11122010.
[29] Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition[J]. EBioMedicine, 2019, 41: 711-716. doi:10.1016/j.ebiom.2019.02.049.
[30] Goulding RE, Chenoweth M, Carter GC, et al. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: a systematic literature review and meta-analysis[J]. Cancer Treat Res Commun, 2020, 24: 100200. doi:10.1016/j.ctarc.2020.100200.
[31] Skoulidis F, Heymach JV. Co-occurring genomic alterations innon-small-cell lung cancer biology and therapy[J]. Nat Rev Cancer, 2019, 19(9): 495-509.
[32] Chang JC, Offin M, Falcon C, et al. Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes[J]. Clin Cancer Res, 2021, 27(14): 4066-4076.
[33] De Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10378): 733-746.
[34] Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation[J]. N Engl J Med, 2022, 387(2): 120-131.
[35] Lee A. Sotorasib: a review in KRAS G12C mutation-positive non-small cell lung cancer. target oncol[J]. 2022, 17(6): 727-733.
[1] FENG Yue, YU Yifan, WU Sijia, LI Hongkai, XUE Fuzhong. Mendelian randomization study of visceral adipose tissue and lung diseases [J]. Journal of Shandong University (Health Sciences), 2024, 62(7): 48-55.
[2] WANG Jingting, WANG Jing, LU Yi, LI Jingtan, LI Qiang, JIA Yanfei, MA Xiaoli. Expression and correlation of α5-nAChR and MHC-I in lung adenocarcinoma [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 72-78.
[3] WU Lin, SHI Chenxi, TONG Xing. Pulmonary benign metastasizing leiomyoma: a report of 7 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 78-84.
[4] WANG Yanan, LIANG Chuanjie, JIA Mengqi, YUAN Huiqing. Role of protein disulfide isomerase TMX1 in promoting chemotherapy resistance in lung cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 31-39.
[5] MENG Jianli, WANG Qinggang. Expression and potential mechanism of VPS72 in lung adenocarcinoma/ squamous cell carcinoma by integrated bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 40-49.
[6] WANG Pengfei, WU Yuanning, GAO Tingting, XU Guang, XIA Wei, WEN Peng, MA Qingqing, CAO Lili, ZHANG Jintao, LIANG Ziting, XU Changjuan, GAO Mingxia, DONG Liang. Clinical and imaging characteristics of 12 cases of Birt-Hogg-Dubé syndrome [J]. Journal of Shandong University (Health Sciences), 2023, 61(6): 53-57.
[7] LIU Shibiao, ZHANG Shujun, LI Peilong, DU Lutao, WANG Chuanxin. The cg20657709 site methylation in the early detection of lung adenocarcinoma [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 18-25.
[8] ZHONG Lu, XUE Fuzhong. A Lung cancer risk prediction model based on Bayesian network uncertainty inference [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 86-94.
[9] CHENG Chuanlong, HAN Chuang, FANG Qidi, LIU Ying, YANG Shuxia, CUI Feng, LIU Jingjing, LI Xiujun. Exploring the environmental influencing factors of lung cancer incidence based on geographically and temporally weighted regression model [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 95-102.
[10] YANG Yongqing, ZHAO Peng, WANG Yu, MA Wenjing, TIAN Mimi, CHENG Yani, ZU Lu, LIN Xiangtao. Diagnostic value of extracellular volume fraction in 62 cases of different pathological types of lung cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(2): 88-94.
[11] AI Jiangshan, GAO Huijiang, AI Shiwen, LI Hengyan, SHI Guodong, WEI Yucheng. Diagnostic value of CT radiomics in lung cancer associated with cystic airspaces [J]. Journal of Shandong University (Health Sciences), 2023, 61(12): 70-77.
[12] Mingyong HAN,Xiaoli YU,Fangping ZENG,Bing XIE,Lan LU,Jiaquan QU,Bifeng JIANG,Sihan TANG,Jie TAN,Jin LIANG,Longhui ZHONG,Liu WANG,Xuanzhi ZHAO. Technical procedure of CT-guided intratumoral chemotherapy for lung tumor [J]. Journal of Shandong University (Health Sciences), 2023, 61(11): 11-19.
[13] ZHAO Qidi, WANG Kai, ZHAO Xiaogang, YAN Tao, WANG Yadong, DU Jiajun. Constructing and validating a prognostic model for patients with stage IIIB non-small cell lung cancer based on SEER database [J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 23-37.
[14] HAN Jing, JIA Chunling. Effects of periodontal basic therapy on postoperative pneumonia in patients with lung cancer before thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 113-118.
[15] GAO Zhongxia, ZHANG Ming, FAN Mingde, TAN Chenyang, WANG Mengdi, WANG Chao, FAN Yuefei, DING Shouluan, WANG Chengwei. Efficacy and prognostic factors of gamma knife in treating 81 cases of brain metastases from lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 44-49.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd